Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial - Annals of Oncology
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations - Journal of Thoracic Oncology
Capmatinib (INC280) | Selective MET Inhibitor | MedChemExpress
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Kinase drug discovery 20 years after imatinib: progress and future directions | Nature Reviews Drug Discovery
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
Met Kinase Inhibitor | CAS 658084-23-2 | SCBT - Santa Cruz Biotechnology
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
MET Inhibitors Active in Advanced NSCLC | MedPage Today
Novartis Gets FDA Approval for Targeted Drug Tabrecta for NSCLC - Xtalks
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 | Pharmafile
Merck KGaA matches Novartis with FDA green light for targeted lung cancer drug Tepmetko | Fierce Pharma
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment | HTML
Representative chemical structures of c-MET and HSP90 inhibitors given... | Download Scientific Diagram
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Novartis' MET inhibitor Tabrecta wins permit for lung cancer in Korea < Pharma < 기사본문 - KBR
